Clinical Trials

Inclusion Criteria:

• Adults referred for clinical assessment due to unexplained or worsening dyspnea and/or suspected Pulmonary Hypertension (PH).
• No absolute contraindications to exercise testing, such as uncontrolled cardiac arrhythmias causing symptoms or hemodynamic compromise.
• Able and willing to provide written informed consent.
• Able and willing to perform submaximal incremental cardiopulmonary exercise test (SHAPE iCPET).
• For Aim 2 specifically, only those patients with right-heart catheterization diagnosis of Pulmonary Arterial Hypertension (PAH) will be recruited; that is, patients with evidence of pulmonary venous or post-capillary.

Exclusion Criteria: 

• Resting SpO2 > 85%.
• Dependence upon supplemental O2 to allow performance of submaximal cardiopulmonary exercise test (SHAPE iCPET).
• Physician-determined unsuitability to undergo right-heart catheterization.
• Positive pregnancy test.
• Musculoskeletal or other conditions that would limit the performance of submaximal cardiopulmonary exercise testing.
• Comorbidities including syncope, active endocarditis, myocarditis, or pericarditis, uncontrolled heart failure, uncontrolled asthma, pulmonary edema, and any other disorder that may effect and/or be aggravated by exercise performance including myocardial ischemia, renal failure, or thyrotoxicosis.

For Aim 2:

• PH due to left-heart disease or with unclear/multifactorial mechanisms).   

Eligibility last updated 4/29/22. Questions regarding updates should be directed to the study team contact.